Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Trade-off preferences regarding adjuvant endocrine therapy among women with estrogen receptor-positive breast cancer.

Wouters H, Maatman GA, Van Dijk L, Bouvy ML, Vree R, Van Geffen EC, Nortier JW, Stiggelbout AM.

Ann Oncol. 2013 Sep;24(9):2324-9. doi: 10.1093/annonc/mdt195. Epub 2013 May 23.

PMID:
23709173
2.

Primary-care patients' trade-off preferences with regard to antidepressants.

Wouters H, Van Dijk L, Van Geffen EC, Gardarsdottir H, Stiggelbout AM, Bouvy ML.

Psychol Med. 2014 Aug;44(11):2301-8. doi: 10.1017/S0033291713003103. Epub 2014 Jan 7.

PMID:
24398071
3.

Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up.

Simon R, Latreille J, Matte C, Desjardins P, Bergeron E.

Can J Surg. 2014 Feb;57(1):26-32.

4.

Endocrine therapy for breast cancer: assessing an array of women's treatment experiences and perceptions, their perceived self-efficacy and nonadherence.

Wouters H, Stiggelbout AM, Bouvy ML, Maatman GA, Van Geffen EC, Vree R, Nortier JW, Van Dijk L.

Clin Breast Cancer. 2014 Dec;14(6):460-467.e2. doi: 10.1016/j.clbc.2014.04.005. Epub 2014 Jun 2.

PMID:
24981234
5.

Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence.

Heisig SR, Shedden-Mora MC, von Blanckenburg P, Schuricht F, Rief W, Albert US, Nestoriuc Y.

Psychooncology. 2015 Feb;24(2):130-7. doi: 10.1002/pon.3611. Epub 2014 Jun 21.

PMID:
24953538
6.

Disentangling breast cancer patients' perceptions and experiences with regard to endocrine therapy: nature and relevance for non-adherence.

Wouters H, van Geffen EC, Baas-Thijssen MC, Krol-Warmerdam EM, Stiggelbout AM, Belitser S, Bouvy ML, van Dijk L.

Breast. 2013 Oct;22(5):661-6. doi: 10.1016/j.breast.2013.05.005. Epub 2013 Jun 14.

7.

Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.

Carlson RW, Henderson IC.

Breast Cancer Res Treat. 2003;80 Suppl 1:S19-26; discussion S27-8. Review.

PMID:
14535531
8.

Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer.

Bender CM, Gentry AL, Brufsky AM, Casillo FE, Cohen SM, Dailey MM, Donovan HS, Dunbar-Jacob J, Jankowitz RC, Rosenzweig MQ, Sherwood PR, Sereika SM.

Oncol Nurs Forum. 2014 May;41(3):274-85. doi: 10.1188/14.ONF.274-285.

9.

Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer.

Ejlertsen B, Jensen MB, Mouridsen HT; Danish Breast Cancer Cooperative Group..

Acta Oncol. 2014 Feb;53(2):174-85. doi: 10.3109/0284186X.2013.850738. Epub 2013 Nov 13.

PMID:
24219541
10.

Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.

Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, Hadji P.

Ann Oncol. 2009 Mar;20(3):431-6. doi: 10.1093/annonc/mdn646. Epub 2009 Jan 15.

PMID:
19150950
11.

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.

Goel S, Sharma R, Hamilton A, Beith J.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004562. doi: 10.1002/14651858.CD004562.pub4. Review.

PMID:
19821328
12.
13.

Selecting adjuvant endocrine therapy for breast cancer.

Eneman JD, Wood ME, Muss HB.

Oncology (Williston Park). 2004 Dec;18(14):1733-44, discussion 1744-5, 1748, 1751-4. Review.

14.

Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer.

Neugut AI, Zhong X, Wright JD, Accordino M, Yang J, Hershman DL.

JAMA Oncol. 2016 Oct 1;2(10):1326-1332. doi: 10.1001/jamaoncol.2016.1291.

PMID:
27281650
16.

Adjuvant endocrine therapy for postmenopausal women: Type and duration.

Mayer EL, Burstein HJ.

Breast. 2015 Nov;24 Suppl 2:S126-8. doi: 10.1016/j.breast.2015.07.028. Epub 2015 Aug 14.

PMID:
26279133
17.

Adjuvant endocrine therapy for early breast cancer.

Andreetta C, Smith I.

Cancer Lett. 2007 Jun 18;251(1):17-27. Epub 2006 Dec 5. Review.

PMID:
17150303
18.

Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer.

Paridaens RJ, Gelber S, Cole BF, Gelber RD, Thürlimann B, Price KN, Holmberg SB, Crivellari D, Coates AS, Goldhirsch A.

Breast Cancer Res Treat. 2010 Aug;123(1):303-10. doi: 10.1007/s10549-010-0794-2. Epub 2010 Feb 27.

19.

Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer outcomes in New Zealand?

Seneviratne S, Campbell I, Scott N, Kuper-Hommel M, Kim B, Pillai A, Lawrenson R.

Breast. 2015 Feb;24(1):62-7. doi: 10.1016/j.breast.2014.11.011. Epub 2014 Dec 5.

PMID:
25486877
20.

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N.

J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62.

PMID:
16288118

Supplemental Content

Support Center